ScaleReady Awards G-Rex® Grants to Support Cell and Gene Therapy Manufacturing in California

Core Insights - ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, announced the awarding of eight G-Rex Grants totaling nearly $2 million to recipients of the California Institute for Regenerative Medicine (CIRM) Manufacturing Network program [1][2][3] Funding and Grants - CIRM has created a funding opportunity aimed at enhancing operations of non-profit academic GMP manufacturing facilities and establishing partnerships to solidify California's position as a leader in cell and gene therapy manufacturing [2][3] - The G-Rex Grant Program is a $40 million initiative designed to support the development and manufacturing of cell and gene-modified therapies, with individual grants worth up to $300,000 [6][10] Awardees and Projects - Notable recipients of the G-Rex Grants include: - Dr. Dan Kaufman from UCSD, awarded $125,000 for a novel G-Rex based production system [4] - Dr. Taby Ahsan from City of Hope, awarded $300,000 for CAR-T cell therapy production [4] - Dr. Steve Feldman from Stanford Medicine, awarded $300,000 for CAR-T cell therapies [4] - Dr. Mohamed Abou-el-Enein from USC/CHLA, awarded $300,000 for a non-viral CAR-T cell therapy platform [4] - Dr. Dawn Ward from UCLA, awarded $150,000 for multiple G-Rex based workflows [4] Industry Impact - The G-Rex manufacturing platform is utilized by over 800 organizations and is involved in approximately 50% of CGT clinical trials, as well as five commercially approved CGT drugs [10] - ScaleReady's initiatives, including the LEAN Cell & Gene program, aim to enhance the efficiency and scalability of CGT manufacturing processes [7][11]